SIP
KPTI icon

Stoneridge Investment Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Stoneridge Investment Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,055
Closed -$154K – 315
2016
Q3 		$154K Sell
1,055
-1,109
-51% -$133K 0.02% 256
2016
Q2 		$218K Sell
2,164
-4,112
-66% -$534K 0.03% 249
2016
Q1 		$840K Sell
6,276
-845
-12% -$93.3K 0.12% 169
2015
Q4 		$1.42M Buy
7,121
+142
+2% +$30.7K 0.19% 137
2015
Q3 		$1.1M Buy
6,979
+972
+16% +$260K 0.15% 154
2015
Q2 		$2.45M Buy
+6,007
New +$2.6M 0.3% 96

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Stoneridge Investment Partners's KPTI Position: Q4 2016 in Review

Stoneridge Investment Partners sold out of Karyopharm Therapeutics (KPTI) in Q4 2016, closing a stake of 1,055 shares — an estimated $154K sold.

Stoneridge Investment Partners first reported a position in KPTI in Q2 2015 and held it in 6 quarters. The position peaked at $2.45M in Q2 2015. 86 funds tracked by Wall St. Rank hold KPTI as of Q4 2016.

  • Stoneridge Investment Partners reported no remaining Karyopharm Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Stoneridge Investment Partners sold 1,055 Karyopharm Therapeutics shares in Q4 2016, an estimated $154K.
  • Stoneridge Investment Partners first reported a position in Karyopharm Therapeutics in Q2 2015 and held it in 6 quarters.
  • Stoneridge Investment Partners's Karyopharm Therapeutics position peaked at $2.45M in Q2 2015.
  • 86 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2016.

Based on Stoneridge Investment Partners's 13F filing for Q4 2016, filed 27 Jan 2017.